Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment for myelosuppression

A technology of bone marrow suppression and treatment plan, applied in the direction of treatment, radiotherapy, medical preparations containing active ingredients, etc., can solve the problems of life-threatening patients, reduction of treatment dose, side effects of treatment plan, etc.

Active Publication Date: 2018-05-01
CANTEX PHARMA
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Neutropenia can be caused by a number of different causes, from birth defects to viral infections, but in this context neutropenia is often seen as a side effect of treatment regimens
Neutropenia is a common side effect in patients treated with antineoplastic drugs for cancer, putting patients at risk of serious or even life-threatening infections and delaying treatment and / or necessitating lower treatment doses, resulting in reduced efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment for myelosuppression
  • Treatment for myelosuppression
  • Treatment for myelosuppression

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0243] 6.2 Example 2: ODSH, a heparanoid that interacts with PF4, enhances the efficacy of carboplatin in a mouse xenograft model of human ovarian cancer

[0244] This example demonstrates that adjuvant administration of ODSH enhances the efficacy of carboplatin against human ovarian tumors grown as xenografts in athymic nude mice.

[0245] Materials & Methods ODSH (50 mg / mL stock concentration) was prepared by Pyramid Laboratories, Inc. and stored at room temperature until use. As described further below, ODSH can be administered either intravenously (IV) at a dose of 48 mg / kg and a volume of 10 mL / kg or subcutaneously (SC) at a dose of 24 mg / kg and a volume of 5 mL / kg. Carboplatin obtained from clinical suppliers was stored at 4°C until use. Carboplatin was administered by intraperitoneal injection (IP) at a dose of 80 mg / kg and a volume of 10 mL / kg. Saline solution (0.9% NaCl) was used as a vehicle control for ODSH and was administered by the same route and in the same vo...

Embodiment 3

[0261] 6.3 Example 3: ODSH, a heparanoid that interacts with PF4, alleviates thrombocytopenia and neutropenia, induces thrombopoiesis and neutrophil production and reduces exposure to chemotherapy regimens with myelosuppressive side effects Patient's systemic symptoms

[0262] In an unblinded clinical trial, patients diagnosed with metastatic pancreatic cancer were treated with ODSH as gemcitabine and nab-paclitaxel ( Adjuvant therapy with albumin-bound paclitaxel).

[0263] Inclusion criteria Male and non-pregnant, non-lactating female patients aged 18 to 75 years with histologically confirmed metastatic adenocarcinoma participated in the trial. Other inclusion criteria were: presence of at least one metastatic tumor (measurable by conventional techniques or CT scan), serum CA 19-9 measurement greater than 2 times the upper limit of normal, no local targeted therapy within six months of participation in the trial Radiotherapy or chemotherapy for advanced disease, absolute ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods for attenuating the myelosuppressive side effects of a treatment regimen, promoting platelet production and neutrophil production, and increasing the efficacy of a treatment regimen by administering a heparanoid that interacts with PF4.

Description

[0001] 1. Cross references to related applications [0002] This application is based on 35 U.S.C. § 119(e) requiring U.S. provisional applications 61 / 724,836 (filed November 9, 2012); 61 / 702,207 (filed September 17, 2012); 61 / 678,053 (filed 2012 61 / 668,709 (filed 6 July 2012); 61 / 664,611 (filed 26 June 2012); 61 / 653,362 (filed 30 May 2012); 61 / 648,043 (filed May 16, 2012); 61 / 644,623 (filed May 9, 2012); and 61 / 644,556 (filed May 9, 2012), the entire contents of which are incorporated herein as refer to. 2. Background technology [0003] Platelets play a key role in the coagulation mechanism. Thrombocytopenia below a certain level results in thrombocytopenia, which can be triggered by a range of clinical conditions or disorders and can extend from mild to life-threatening. [0004] Thrombocytopenia can be triggered by diseases or conditions affecting the bone marrow, in which platelet precursors appear before entering the bloodstream; by diseases or conditions affecting ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/727A61K31/715C08B37/10
CPCA61K31/727A61K45/06A61P35/02A61P7/00A61P7/04A61K35/28A61K39/395A61N5/00
Inventor S.马库斯
Owner CANTEX PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com